CA2952875C - Methods to treat inflammation of the lung - Google Patents

Methods to treat inflammation of the lung Download PDF

Info

Publication number
CA2952875C
CA2952875C CA2952875A CA2952875A CA2952875C CA 2952875 C CA2952875 C CA 2952875C CA 2952875 A CA2952875 A CA 2952875A CA 2952875 A CA2952875 A CA 2952875A CA 2952875 C CA2952875 C CA 2952875C
Authority
CA
Canada
Prior art keywords
subject
leukotoxin
ltxa
lung
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2952875A
Other languages
English (en)
French (fr)
Other versions
CA2952875A1 (en
Inventor
Scott KACHLANY
Benjamin BELINKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Actinobac Biomed Inc
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actinobac Biomed Inc, Rutgers State University of New Jersey filed Critical Actinobac Biomed Inc
Publication of CA2952875A1 publication Critical patent/CA2952875A1/en
Application granted granted Critical
Publication of CA2952875C publication Critical patent/CA2952875C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2952875A 2014-06-20 2015-06-19 Methods to treat inflammation of the lung Active CA2952875C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462014967P 2014-06-20 2014-06-20
US62/014,967 2014-06-20
PCT/US2015/036814 WO2015196159A1 (en) 2014-06-20 2015-06-19 Methods to treat inflammation of the lung

Publications (2)

Publication Number Publication Date
CA2952875A1 CA2952875A1 (en) 2015-12-23
CA2952875C true CA2952875C (en) 2022-06-28

Family

ID=54868677

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2952875A Active CA2952875C (en) 2014-06-20 2015-06-19 Methods to treat inflammation of the lung

Country Status (5)

Country Link
US (1) US9724384B2 (enExample)
EP (1) EP3157542B1 (enExample)
JP (1) JP6649376B2 (enExample)
CA (1) CA2952875C (enExample)
WO (1) WO2015196159A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4054662T (lt) * 2019-11-08 2024-08-12 Hollister Incorporated Hidrofiliniai medicinos produktai ir drėkinimo terpės jiems drėkinti

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199125B2 (en) * 2003-10-02 2007-04-03 Bristol-Myers Squibb Company Spiro-cyclic compounds useful as anti-inflammatory agents
US8053406B2 (en) 2005-11-25 2011-11-08 University Of Medicine And Dentistry Of New Jersey Compositions for the treatment of cancer, and methods for testing and using the same
WO2012125942A1 (en) 2011-03-16 2012-09-20 University Of Medicine And Dentistry Of New Jersey Combination therapy with leukotoxin
WO2007062150A2 (en) 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Leukotoxin compositions and therapeutic methods
US8926990B2 (en) * 2009-10-13 2015-01-06 Rutgers, The State University Of New Jersey Treatment and diagnosis of inflammatory disorders and HIV
US20090257957A1 (en) 2008-04-15 2009-10-15 John Burnier Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
EP2488198B1 (en) * 2009-10-13 2016-09-28 Rutgers, the State University of New Jersey Treatment and diagnosis of autoimmune disorders
WO2014210454A1 (en) * 2013-06-27 2014-12-31 Rutgers, The State University Of New Jersey Treatment and diagnosis of ocular disease

Also Published As

Publication number Publication date
US9724384B2 (en) 2017-08-08
JP2017524732A (ja) 2017-08-31
EP3157542A1 (en) 2017-04-26
WO2015196159A1 (en) 2015-12-23
EP3157542A4 (en) 2018-02-07
CA2952875A1 (en) 2015-12-23
JP6649376B2 (ja) 2020-02-19
EP3157542B1 (en) 2024-12-25
US20150366937A1 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
US20210052590A1 (en) Carbonic anhydrase enzymes for regulating mast cell hematopoiesis and type 2 inflammation
US20220048948A1 (en) Cd40 targeted peptides and uses thereof
CN111741763B (zh) 包含apl型肽的药用组合物
US9950030B2 (en) Treatment and diagnosis of ocular disease
TW202402790A (zh) 減少呼吸系統感染之方法
US20240261336A1 (en) Treatment of chronic obstructive pulmonary disease and lung degeneration using activated fibroblasts and exosome derivatives thereof
CN112188901A (zh) 用于治疗哮喘或变应性疾病的方法
CA2952875C (en) Methods to treat inflammation of the lung
JP2025000998A (ja) ニューロメジンペプチドを使用して２型サイトカイン媒介性炎症を低減させる方法
KR20100022044A (ko) 면역 조절제 화합물을 이용한 알레르기성 질환의 치료 방법
WO2004089292A2 (en) Immunomodulatory agents for treatment of inflammatory diseases
Geng et al. The association between CD46 expression in B cells and the pathogenesis of airway allergy
WO2021127008A1 (en) Compositions and methods for treating neuromuscular disorders
US20230338492A1 (en) Aldh1 antigen-pulsed dendritic cells
Fuhlbrigge et al. Children and asthma in America 2004 survey
WO2024018442A1 (en) Preferential depletion of tcf1+ progenitor t-cells in severe covid-19 as mediated by interleukin 12 (il-12)
WO2025244639A1 (en) Methods for treating lung diseases and disorders
WO2016049156A1 (en) Compositions and methods for treating lung remodeling diseases
WO2025155743A1 (en) Chemokine ligand 18 (ccl18) for diagnosis and treatment of inflammatory lung disease
Patel The Role of Neutrophils and Their Proteases in Allergic Airway Disease
Banchereau Cells and Cytokines in Lung Inflammation
Gattazzo Role of inflammation in the development of lung fibrosis and in the pathogenesis of pulmunary hypertension

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200602

EEER Examination request

Effective date: 20200602

EEER Examination request

Effective date: 20200602

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250613

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250613